Infectious Diseases

Medicine & Life Sciences

1. Transplant Recipients 100%
2. HIV 91%
3. Cytomegalovirus 90%
4. Infections 83%
5. Coronavirus 61%
6. Transplants 58%
7. Adenoviridae 53%
8. Cytomegalovirus Infections 51%
9. Liver Transplantation 48%
10. T-Lymphocytes 45%
11. HIV-1 44%
12. Therapeutics 41%
13. Antiviral Agents 39%
14. Virus Diseases 38%
15. HIV Infections 38%
16. Viruses 36%
17. Vaccines 36%
18. Organ Transplantation 31%
19. Endocarditis 31%
20. Equipment and Supplies 30%
21. Apoptosis 28%
22. Hepacivirus 28%
23. SARS Virus 27%
24. Human Herpesvirus 6 26%
25. Opportunistic Infections 25%
26. Mortality 24%
27. Serogroup 24%
28. Transplantation 24%
29. Community-Based Participatory Research 22%
30. Pharmaceutical Preparations 21%
31. Vaccination 21%
32. Severe Acute Respiratory Syndrome 19%
33. Tuberculosis 19%
34. Bacteremia 19%
35. Retroviridae Infections 19%
36. Immunization 18%
37. Refugees 18%
38. Kidney 18%
39. Pandemics 17%
40. Ganciclovir 17%
41. Protease Inhibitors 17%
42. Genes 17%
43. Allografts 16%
44. Joints 16%
45. Human Influenza 16%
46. Proteins 16%
47. Propionic Acidemia 15%
48. Cell Death 15%
49. Genetic Therapy 15%
50. Chronic Hepatitis C 15%
51. Tissue Donors 15%
52. Epidemiology 15%
53. DNA 14%
54. Viremia 14%
55. Immunocompromised Host 13%
56. Population 13%
57. Liver 13%
58. Lung 13%
59. Confidence Intervals 12%
60. HIV Protease Inhibitors 12%
61. Hematopoietic Stem Cells 12%
62. Incidence 12%
63. Valganciclovir 12%
64. Monoclonal Antibodies 12%
65. Adenovirus Vaccines 12%
66. Viral Load 11%
67. Cohort Studies 11%
68. Human Adenoviruses 11%
69. Cryptococcosis 11%
70. Mycoses 11%
71. Anti-Bacterial Agents 11%
72. Caspase 8 11%
73. In Vitro Techniques 11%
74. Ritonavir 11%
75. Hospitalization 11%
76. Safety 11%
77. Polymerase Chain Reaction 11%
78. Fever 10%
79. Herpesviridae Infections 10%
80. Acquired Immunodeficiency Syndrome 10%
81. Reverse Transcriptase Inhibitors 10%
82. Hematopoietic Stem Cell Transplantation 10%
83. Toll-Like Receptor 2 10%
84. AIC246 10%
85. Communicable Diseases 10%
86. lens epithelium-derived growth factor 10%
87. Ribavirin 10%
88. Nelfinavir 9%
89. Human Herpesvirus 7 9%
90. Peptides 9%
91. Highly Active Antiretroviral Therapy 9%
92. Morbidity 9%
93. Anti-Retroviral Agents 9%
94. Feline Immunodeficiency Virus 9%
95. Staphylococcus aureus 9%
96. Antigens 9%
97. Kidney Transplantation 9%
98. Ligands 9%
99. Invasive Fungal Infections 9%
100. Heme Oxygenase-1 9%